Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease have?
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease has 563 citations in the OpenAlex counts ScholarIQ stores.
When was Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease published?
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease has 2020 year in the ScholarIQ index.
What is the open-access status of Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease?
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease has gold oa status in the ScholarIQ index.
What is the DOI of Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease?
The DOI for Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease is on the source record.
What is the PMID of Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease?
The PMID for Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease is on the source record.
What is the OpenAlex record for Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease?
The OpenAlex for Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease is on the source record.